.jpeg)
2026-04-09 05:45:58
Pirtobrutinib, an innovative non-covalent BTK inhibitor, provides a treatment option for patients with relapsed/refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), featuring a unique mechanism and manageable safety profile.
2026-04-09 05:34:17
Provides a comprehensive interpretation of the findings from the POLAR phase II basket trial, published in Nature Medicine in March 2026. It details the efficacy, biomarker analysis, and clinical value of olaparib (a PARP inhibitor) combined with pembrolizumab (an anti-PD-1 immunotherapy) as biomarker-guided maintenance therapy for patients with metastatic pancreatic cancer who achieved disease control after platinum-based chemotherapy, offering cutting-edge clinical reference for the precision treatment of pancreatic cancer.
2026-04-09 05:22:20
This article systematically reviews the basic pharmaceutical properties, anti-tumor mechanism of action, approved indications, standard dosage and administration, pre-infusion preparation, and adverse event management of Sacituzumab Govitecan, providing a professional and comprehensive medication reference for oncology patients and clinical healthcare providers.
2026-04-07 04:45:06
The drug properties and mechanism of action of Fulvestrant (brand name Faslodex), systematically sorts out its indications, standard dosage, dose adjustment rules, adverse reactions and safety precautions for single-agent and combined treatment of breast cancer, providing professional reference for clinical diagnosis and treatment as well as patient medication.
2026-04-07 03:22:33
The clinical medication regimen of Avatrombopag (brand name Doptelet) 20mg specification, details the initial dose, adjustment rules and personalized medication principles for immune thrombocytopenia and chronic liver disease-related thrombocytopenia, to provide professional reference for clinical safe medication.
2026-04-07 02:55:19
This article explains the core pharmacological mechanism of Gilteritinib (brand name Xospata) in the treatment of FLT3-mutated acute myeloid leukemia (AML), and sorts out the relevant impacts of drug discontinuation on disease control and clinical outcomes, to provide professional reference for clinical medication decision-making.
2026-04-03 07:03:54
Avatrombopag (brand name Doptelet) and Hetrombopag are both oral thrombopoietin (TPO) receptor agonists, core treatments for thrombocytopenia. While sharing a homologous mechanism of action, they have clear differences in molecular structure, global indication coverage, clinical application scenarios, and pharmacokinetic profiles. This article explains their key distinctions and clinical selection logic.
2026-04-03 06:57:16
Deucravacitinib (brand name Sotyktu, Chinese trade name Songdiduo) is a next-generation, oral, highly selective TYK2 inhibitor developed for the pathological mechanism of psoriasis. Approved in multiple countries and regions worldwide for the systemic treatment of adults with moderate-to-severe plaque psoriasis, it precisely modulates inflammatory pathways to improve skin lesions, with the advantages of rapid onset, durable long-term efficacy, and convenient oral administration, providing a non-injectable, non-biologic treatment option for patients with psoriasis.
2026-04-03 06:50:04
Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) is a next-generation fixed-dose combination (FDC) antiretroviral therapy for HIV. It features minimal food dependence, with consistent absorption and antiviral efficacy whether taken with or without food. The core clinical principle is consistent daily dosing at a fixed time to maintain long-term viral suppression.
2026-04-03 06:26:16
Valganciclovir (Valcyte) is a core antiviral for CMV prevention and treatment in transplant and immunocompromised patients. Its duration is individualized based on immune status, transplant type, virologic monitoring, and risk stratification, balancing efficacy and safety against myelosuppression.
2026-04-03 06:19:35
Cabergoline is a highly selective long-acting dopamine D2 receptor agonist, the first-line treatment for hyperprolactinemia (HPRL), pituitary prolactinoma, and physiological lactation suppression. Its core clinical dosing strategy follows low-dose initiation with gradual individualized titration. This article details its full clinical specifications, including dosing regimens, dose adjustment principles, indication-specific treatment duration, and post-discontinuation monitoring.
2026-04-03 06:00:38
Rucaparib (brand name Rubraca) is a highly selective oral PARP inhibitor, granted full regular approval by the U.S. FDA on December 17, 2025, for the treatment of adult patients with deleterious BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC). This approval is based on pivotal data from the phase III TRITON3 trial, marking the conversion from accelerated approval to full approval, and providing a new precision targeted therapy option for patients with advanced prostate cancer.
